Biotech Values

[mcbio]

GILD licenses gene-editing approach to HBV from (private) Precision Biosciences

Thanks for this. Well, I guess I like that GILD has an interest in targeting cccDNA though for biased reasons I'd like to see them extend this interest to ASMB. ; )

I've been meaning to circle back to the recent ARWR data to see what impact, if any, it may have on ASMB and the other HBV players. Just haven't had the time yet.